Cosmo Pharmaceuticals NV

COPN

Company Profile

  • Business description

    Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.

  • Contact

    Sir John Rogerson’s Quay
    Riverside II
    Dublin2
    IRL

    T: +353 18170370

    E: [email protected]

    https://www.cosmopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    332

Stocks News & Analysis

stocks

Undervalued by 17%, this US cybersecurity leader is a buy for 2026

Here’s a wide-moat company with strong secular tailwinds in a promising industry—and an attractive stock price, too.
stocks

Tough conditions for ASX listed wagering leader

Wagering continues to be challenged in Australia.
stocks

Chart of the Week: Inflation fears dampen sentiment on retailers

Rising inflation is the fly in the ointment.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,045.9027.80-0.31%
CAC 408,325.1891.261.11%
DAX 4025,261.64134.180.53%
Dow JONES (US)49,504.07237.960.48%
FTSE 10010,108.3263.630.63%
HKSE26,231.7982.480.32%
NASDAQ23,671.35191.330.81%
Nikkei 22551,939.89822.631.61%
NZX 50 Index13,696.2520.61-0.15%
S&P 5006,966.2844.820.65%
S&P/ASX 2008,717.8029.10-0.33%
SSE Composite Index4,120.4337.450.92%

Market Movers